A silent shift is unfolding in the world of neurology that few outside the medical community are talking about. But for patients, families, and biotech investors, the change is nothing short of monumental. The rise of targeted therapies and genetic innovation is propelling an under-the-radar sector into the spotlight: the Peripheral Myelin Protein 22 (PMP22) Gene-Related Disorder...